Dan Cimpoeru | Board Member
European Cancer Patient Coalition

Dan Cimpoeru, Board Member, European Cancer Patient Coalition

Dan Cimpoeru was elected a Board Member of the European Cancer Patient Coalition in 2016. The European Cancer Patient Coalition has over 400 members, and is Europe’s largest umbrella cancer patients’ association, covering all 28 EU member states as well as many other European and non-European countries.

He is a lawyer and from this position he has participated in the patient advocacy movement since 2007, being deeply involved in defending Romanian patients' rights in court. In 2014-2015, based on the European Directive 89/105/EEC, he won 17 lawsuits against the Romanian government and due to this work, 165 Romanian cancer patients are now receiving medical treatment for free.

Dan is an Associate Professor of Law at the University of Bucharest and an author of numerous scientific articles and several books including "Malpractice", a reference work in the Romanian publishing environment. He is particularly interested in the legal aspects of drug policy such as Health Technology Assessment, pricing and reimbursement, biologics/biosimilars, and compassionate use. He has written and spoken extensively on these topics.

He has a PhD in Constitutional Law from the University of Bucharest and a is legal consultant and expert for the World Health Organization.


Biosimilars Day 1 - Tuesday 31st October 2017 @ 09:50

International stakeholders panel discussion: What does it take to get biosimilars moving in a country?

  • Consisting of industry panellists, physicians, pharmacists, patient advocacy groups, payers, regulators and health authorities, the 360° Perspective Panel allows the whole industry to come together to discuss and debate the sector’s most pertinent topics of the day.
  • With no guarantee that physicians will prescribe biosimilars interchangeably with reference products, what more does the industry need to do to encourage biosimilar uptake within healthcare?
  • What can we learn from gainsharing practices? Carrot & stick models, which works better?
  • How influential are payers in the speed in which biosimilars are taken up in healthcare systems?
  • How does the industry envisage overcoming the challenge that patient communities are generally unaware of this new, yet important, category of medicines?

back to speakers